Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
24.06
-1.09 (-4.33%)
At close: Mar 3, 2025, 4:00 PM
24.36
+0.30 (1.25%)
Pre-market: Mar 4, 2025, 7:37 AM EST
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,100,517
Profits / Employee
-$278,701
Market Cap
3.02B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
APLS News
- 4 days ago - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 8 days ago - Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 12 days ago - Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 18 days ago - Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 27 days ago - Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA) - GlobeNewsWire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect - Accesswire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out - Accesswire